82 results
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
9 May 24
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results
4:12pm
-888-886-7786 (domestic) or 1-416-764-8658 (international) and refer to Conference ID 71864759. To access the webcast, click here. For instant telephone … access, click the Call me™ link here. Following the live event, a replay will be available on the Investors section of the Company’s website.
ABOUT
DEFA14A
CRNX
Crinetics Pharmaceuticals Inc
25 Apr 24
Additional proxy soliciting materials
4:48pm
. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained … located in the box above available when you access the website and follow the instructions. SEE REVERSE FOR FULL AGENDA Copyright © 2024 BetaNXT, Inc
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals Inc
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
and access to care for patients and medical providers. In some cases, you can identify forward-looking statements by terms such as “may,” “believe … -specified Reducing treatment burden endpoints in patients not medically treated who Reducing access barriers had elevated IGF-1 levels at baseline Delivering
8-K
gt0m5wyybcstjqs3mk5b
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
8-K
EX-99.1
vobdc9uftnb2vd
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
8-K
EX-99.1
buyxxhmz3s9
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
8-K
EX-10.1
k1n3bvsvh
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
8-K
EX-10.2
tq9b831zqungu
1 Mar 24
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
4:07pm
8-K
EX-99.1
uj75 nej1u
28 Feb 24
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
EX-99.1
33m2p9 il4r85
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
j3qflzv9tk82s 69j
8 Jan 24
Regulation FD Disclosure
8:03am
8-K
EX-99.1
3acjsqomka16h
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-3.1
w67hzi1
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:35pm
8-K
EX-1.1
eaz6og9xh7l2ck9b
13 Sep 23
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
5:23pm
424B5
4d68v4rh
13 Sep 23
Prospectus supplement for primary offering
5:19pm
424B5
yguoh3bh
11 Sep 23
Prospectus supplement for primary offering
4:09pm